The Online Investor

Slideshow Stock Splits

By The Online Investor Staff, updated Mon., Oct. 3, 2:51 PM

Slide #6. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) 1 for 14 Reverse Split

Announced: 9/16/2022
Stock Split: 1 for 14
Record Date: 9/16/2022
Pay Date: 9/19/2022
SONN Optionable?: No

Sonnet BioTherapeutics Holdings is a clinical-stage biopharmaceutical company with a proprietary technology for developing biologic medicines it refers to as FHAB (Fully Human Albumin Binding). Co. has a pipeline of therapeutic compounds focused primarily on oncology indications of unmet medical need, including SON-080, a low-dose formulation of Interleukin 6 which is in development for Chemotherapy Induced Peripheral Neuropathy; SON-1010, which is being developed for solid tumor indications, including non-small cell lung cancer and head and neck cancer, as well as for antiviral applications; and SON-1210, which is being developed for solid tumor indications, including colorectal cancer.
SONN Detailed Information Page & Split History »

Company Name: 
Sonnet BioTherapeutics Holdings Inc
Website: 
www.sonnetbio.com
Sector: 
Biotechnology
Number of ETFs Holding SONN: 
2
Total Market Value Held by ETFs: 
$2.35M
Total Market Capitalization: 
$6.00M
% of Market Cap. Held by ETFs: 
39.16%

Open the SONN Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree SONN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
74th percentile
(ranked higher than approx. 74% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Stock Splits Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.